Arkolith/Insider Trading/LGND/Form 4

Espinoza Octavio

Chief Financial OfficerLIGAND PHARMACEUTICALS INC (LGND) · full profile →Form 4 · filed Mar 6, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2.8M
Net Open-Market Flow
-$2.8M
Transactions
15
13 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 4, 2026Sell(S)950$201.73$192K33K
Mar 4, 2026Sell(S)3K$208.80$713K22K
Mar 4, 2026Sell(S)2K$207.91$511K25K
Mar 4, 2026Option exercise(M)2K$58.49$94K35K
Mar 4, 2026Option exercise(M)466$80.72$38K35K
Mar 4, 2026Sell(S)699$198.71$139K34K
Mar 4, 2026Sell(S)53$200.08$11K34K
Mar 4, 2026Sell(S)698$201.09$140K34K
Mar 4, 2026Sell(S)697$202.79$141K32K
Mar 4, 2026Sell(S)668$203.63$136K31K
Mar 4, 2026Sell(S)743$204.74$152K31K
Mar 4, 2026Sell(S)1K$205.79$300K29K
Mar 4, 2026Sell(S)2K$206.89$329K28K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 4, 2026Option exercise(M)2K—$00
Mar 4, 2026Option exercise(M)466—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002001011-26-000023) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML